| Leukemia, Myelocytic, Acute
Trisenox vs Rydapt
Side-by-side clinical, coverage, and cost comparison for leukemia, myelocytic, acute.Deep comparison between: Trisenox vs Rydapt with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRydapt has a higher rate of injection site reactions vs Trisenox based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rydapt but not Trisenox, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Trisenox
Rydapt
At A Glance
Intravenous
Daily
Arsenical antineoplastic
Oral
Twice daily
Multi-kinase inhibitor
Indications
- Leukemia, Myelocytic, Acute
- Leukemia, Myelocytic, Acute
- Aggressive Systemic Mastocytosis
- Systemic mastocytosis with associated clonal, hematologic non-mast-cell lineage disease
- Leukemia, Mast-Cell
Dosing
Acute Promyelocytic Leukemia (newly-diagnosed low-risk) Induction: 0.15 mg/kg/day IV daily in combination with tretinoin until bone marrow remission, not to exceed 60 days. Consolidation: 0.15 mg/kg/day IV daily for 5 days per week during weeks 1-4 of each 8-week cycle for 4 cycles in combination with tretinoin.
Acute Promyelocytic Leukemia (relapsed or refractory) Induction: 0.15 mg/kg/day IV daily until bone marrow remission, not to exceed 60 days. Consolidation: 0.15 mg/kg/day IV daily for 25 doses over a period of up to 5 weeks, beginning 3 to 6 weeks after completion of induction.
Leukemia, Myelocytic, Acute 50 mg orally twice daily with food on Days 8 to 21 of each induction cycle with cytarabine and daunorubicin and on Days 8 to 21 of each consolidation cycle with high-dose cytarabine.
Aggressive Systemic Mastocytosis, Systemic mastocytosis with associated clonal, hematologic non-mast-cell lineage disease, Leukemia, Mast-Cell 100 mg orally twice daily with food; continue until disease progression or unacceptable toxicity.
Contraindications
- Hypersensitivity to arsenic
- Hypersensitivity to midostaurin or any excipient, including reactions such as anaphylactic shock, dyspnea, flushing, chest pain, and angioedema
Adverse Reactions
Most common (>=30%) Nausea, cough, fatigue, pyrexia, headache, abdominal pain, vomiting, tachycardia, diarrhea, dyspnea, hypokalemia, leukocytosis, hyperglycemia, hypomagnesemia, insomnia, dermatitis, edema, QTc prolongation, rigors, sore throat, arthralgia, paresthesia, pruritus
Serious Differentiation syndrome, cardiac conduction abnormalities, QTc prolongation, encephalopathy, hepatotoxicity, hyperleukocytosis, atrial dysrhythmias, hyperglycemia
Postmarketing Ventricular tachycardia, torsade de pointes, atrioventricular block, congestive heart failure, deafness, pancytopenia, bone marrow necrosis, peripheral neuropathy, seizures, confusion, encephalopathy, Wernicke's encephalopathy, posterior reversible encephalopathy syndrome, toxic epidermal necrolysis, rhabdomyolysis, melanoma, pancreatic cancer, squamous cell carcinoma
Most common (>=20%) - AML Febrile neutropenia, nausea, mucositis, vomiting, headache, petechiae, musculoskeletal pain, epistaxis, device-related infection, hyperglycemia, ECG QT prolonged, upper respiratory tract infections
Most common (>=20%) - Systemic Mastocytosis Nausea, vomiting, diarrhea, edema, musculoskeletal pain, abdominal pain, fatigue, upper respiratory tract infection, constipation, pyrexia, headache, dyspnea
Serious Pulmonary toxicity, febrile neutropenia, sepsis, gastrointestinal hemorrhage, pneumonia, cardiac events
Postmarketing Interstitial lung disease, acute febrile neutrophilic dermatosis (Sweet syndrome)
Pharmacology
The mechanism of action is not completely understood. Arsenic trioxide causes morphological changes and DNA fragmentation characteristic of apoptosis in promyelocytic leukemia cells and causes damage or degradation of the PML-RAR-alpha fusion protein.
Midostaurin is a multi-kinase inhibitor that inhibits wild type and mutant FLT3, KIT (wild type and D816V), PDGFRalpha/beta, and members of the PKC serine/threonine kinase family, inducing apoptosis in leukemic cells expressing FLT3 mutations and inhibiting KIT signaling and histamine release in mast cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Trisenox
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
No coverage data available for Rydapt.
UnitedHealthcare
Trisenox
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
No coverage data available for Rydapt.
Humana
Trisenox
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
No coverage data available for Rydapt.
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableHealthWell: Acute Myeloid Leukemia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$25/momo
Novartis Oncology Universal Co-pay Program: RydaptCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TrisenoxView full Trisenox profile
RydaptView full Rydapt profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.